US20110150890A1 - Use of cgrp antagonist compounds for treatment of psoriasis - Google Patents

Use of cgrp antagonist compounds for treatment of psoriasis Download PDF

Info

Publication number
US20110150890A1
US20110150890A1 US13/039,075 US201113039075A US2011150890A1 US 20110150890 A1 US20110150890 A1 US 20110150890A1 US 201113039075 A US201113039075 A US 201113039075A US 2011150890 A1 US2011150890 A1 US 2011150890A1
Authority
US
United States
Prior art keywords
cgrp
psoriasis
cgrp antagonist
piperidinyl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/039,075
Other languages
English (en)
Inventor
Birkir SVEINSSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US13/039,075 priority Critical patent/US20110150890A1/en
Publication of US20110150890A1 publication Critical patent/US20110150890A1/en
Priority to US13/969,288 priority patent/US9585940B2/en
Priority to US15/355,723 priority patent/US10668132B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5753—Calcitonin gene related peptide
US13/039,075 2002-08-12 2011-03-02 Use of cgrp antagonist compounds for treatment of psoriasis Abandoned US20110150890A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US13/039,075 US20110150890A1 (en) 2002-08-12 2011-03-02 Use of cgrp antagonist compounds for treatment of psoriasis
US13/969,288 US9585940B2 (en) 2002-08-12 2013-08-16 Use of CGRP antagonist compounds for treatment of psoriasis
US15/355,723 US10668132B2 (en) 2002-08-12 2016-11-18 Use of CGRP antagonist compounds for treatment of psoriasis

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IS6496 2002-08-12
IS6496 2002-08-12
PCT/IS2003/000023 WO2004014351A2 (en) 2002-08-12 2003-08-12 Use of cgrp antagonist compounds for treatment of psoriasis
US52410405A 2005-02-10 2005-02-10
US13/039,075 US20110150890A1 (en) 2002-08-12 2011-03-02 Use of cgrp antagonist compounds for treatment of psoriasis

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
US10524104 Continuation 2003-08-12
PCT/IS2003/000023 Continuation WO2004014351A2 (en) 2002-08-12 2003-08-12 Use of cgrp antagonist compounds for treatment of psoriasis
US52410405A Continuation 2002-08-12 2005-02-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/969,288 Continuation US9585940B2 (en) 2002-08-12 2013-08-16 Use of CGRP antagonist compounds for treatment of psoriasis

Publications (1)

Publication Number Publication Date
US20110150890A1 true US20110150890A1 (en) 2011-06-23

Family

ID=36701412

Family Applications (5)

Application Number Title Priority Date Filing Date
US13/039,075 Abandoned US20110150890A1 (en) 2002-08-12 2011-03-02 Use of cgrp antagonist compounds for treatment of psoriasis
US13/969,288 Active 2024-05-23 US9585940B2 (en) 2002-08-12 2013-08-16 Use of CGRP antagonist compounds for treatment of psoriasis
US15/355,723 Active 2037-09-06 US10668132B2 (en) 2002-08-12 2016-11-18 Use of CGRP antagonist compounds for treatment of psoriasis
US16/888,708 Active US11266718B2 (en) 2002-08-12 2020-05-30 Methods of treating inflammatory skin disorders
US17/969,971 Abandoned US20230181693A1 (en) 2002-08-12 2022-10-20 Methods of treating inflammatory skin disorders

Family Applications After (4)

Application Number Title Priority Date Filing Date
US13/969,288 Active 2024-05-23 US9585940B2 (en) 2002-08-12 2013-08-16 Use of CGRP antagonist compounds for treatment of psoriasis
US15/355,723 Active 2037-09-06 US10668132B2 (en) 2002-08-12 2016-11-18 Use of CGRP antagonist compounds for treatment of psoriasis
US16/888,708 Active US11266718B2 (en) 2002-08-12 2020-05-30 Methods of treating inflammatory skin disorders
US17/969,971 Abandoned US20230181693A1 (en) 2002-08-12 2022-10-20 Methods of treating inflammatory skin disorders

Country Status (23)

Country Link
US (5) US20110150890A1 (no)
EP (1) EP1556020B1 (no)
JP (1) JP2006501216A (no)
KR (1) KR101070213B1 (no)
CN (1) CN1674919A (no)
AT (1) ATE423553T1 (no)
AU (1) AU2003260944B2 (no)
BR (1) BR0313388A (no)
CA (1) CA2495498C (no)
DE (1) DE60326370D1 (no)
DK (1) DK1556020T3 (no)
EA (1) EA008744B1 (no)
ES (1) ES2323170T3 (no)
IL (1) IL166761A (no)
IS (1) IS2902B (no)
MX (1) MXPA05001649A (no)
NO (1) NO20051262L (no)
NZ (1) NZ538615A (no)
PL (1) PL375536A1 (no)
PT (1) PT1556020E (no)
RS (1) RS52750B (no)
SI (1) SI1556020T1 (no)
WO (1) WO2004014351A2 (no)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10668132B2 (en) 2002-08-12 2020-06-02 Nepsone Ehf Use of CGRP antagonist compounds for treatment of psoriasis
US11433119B2 (en) * 2016-11-18 2022-09-06 Nepsone Ehf Methods of treating inflammatory skin disorders

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
ES2433251T5 (es) * 2005-11-14 2020-03-13 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina y procedimientos que utilizan los mismos
NZ587292A (en) 2008-03-04 2012-09-28 Pfizer Ltd Use of anti-CGRP (calcitonin gene-related peptide) antagonists to treat chronic pain
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
WO2011024113A1 (en) 2009-08-28 2011-03-03 Rinat Neuroscience Corporation Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
CN107827982B (zh) 2011-05-20 2021-07-06 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
SI3495392T1 (sl) 2011-05-20 2021-11-30 H. Lundbeck A/S Sestavki proti CGRP in uporaba le-teh
AR086515A1 (es) 2011-05-20 2013-12-18 Alderbio Holdings Llc Uso de anticuerpos o fragmentos de anticuerpos anti-cgrp o anti-cgrp-r para tratar o prevenir las formas cronicas y agudas de la diarrea
JP5923375B2 (ja) * 2012-04-24 2016-05-24 花王株式会社 Ｃｇｒｐ応答性促進剤
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
UA123759C2 (uk) 2014-03-21 2021-06-02 Тева Фармасьютікалз Інтернешнл Гмбх Застосування моноклонального антитіла, яке інгібує шлях пов'язаного з геном кальциноніну пептиду (cgrp), для лікування або зниження частоти випадків мігренозного головного болю у суб'єкта
EP3194435A1 (en) 2014-09-15 2017-07-26 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
US10538561B2 (en) 2015-01-22 2020-01-21 Isanaka Ram Peptide for treating inflammatory diseases
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
WO2017001434A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
WO2017001433A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
US10392434B2 (en) 2016-09-23 2019-08-27 Teva Pharmaceuticals International Gmbh Treating refractory migraine
US11400136B2 (en) 2017-06-19 2022-08-02 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
AU2018362018A1 (en) * 2017-11-06 2020-06-25 Auckland Uniservices Limited Peptide conjugate CGRP receptor antagonists and methods of preparation and uses thereof
EA202092335A1 (ru) 2018-04-02 2021-01-22 Эмджен Инк. Композиции на основе эренумаба и пути их применения
WO2019213660A2 (en) * 2018-05-04 2019-11-07 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
AU2020206241A1 (en) 2019-01-08 2021-08-26 H. Lundbeck A/S Acute treatment and rapid treatment of headache using anti-CGRP antibodies
WO2020153520A1 (ko) * 2019-01-25 2020-07-30 (주)아모레퍼시픽 벤조산아마이드 화합물 및 용해보조제를 포함하는 조성물
AR126954A1 (es) * 2021-09-02 2023-12-06 Biohaven Pharm Holding Co Ltd Métodos para tratar la psoriasis con uno o más antagonistas de receptores de cgrp

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6019967A (en) * 1995-01-26 2000-02-01 Societe L'oreal S.A. Therapeutic/cosmetic compositions comprising CGRP antagonists for treating sensitive human skin

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005221A1 (en) * 1994-08-16 1996-02-22 Human Genome Sciences, Inc. Calcitonin receptor
FR2732221B1 (fr) * 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
FR2732220B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les lichens et les prurits et composition obtenue
EP0737471A3 (fr) 1995-04-10 2000-12-06 L'oreal Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
AU4261697A (en) * 1996-09-09 1998-03-26 Smithkline Beecham Corporation Compounds and methods
WO1998056779A1 (en) * 1997-06-13 1998-12-17 Smithkline Beecham Corporation 4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists
US6214816B1 (en) * 1998-03-17 2001-04-10 Novo Nordisk A/S Heterocyclic compounds
ES2137136B1 (es) * 1998-05-18 2000-07-01 Esteve Labor Dr Empleo de derivados de aril (o heteroaril) azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de la inflamacion neurogenica.
CA2345357A1 (en) * 1998-09-30 2000-04-06 Merck Sharp & Dohme Limited Benzimidazolinyl piperidines as cgrp ligands
US6313097B1 (en) 1999-03-02 2001-11-06 Boehringer Ingelheim Pharma Kg Antagonists of calcitonin gene-related peptide
DE19911039A1 (de) 1999-03-12 2000-09-14 Boehringer Ingelheim Pharma Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO2002060480A1 (en) 2001-02-01 2002-08-08 Biogen, Inc. Methods for treating or preventing skin disorders using cd2-binding agents
DE60326370D1 (de) 2002-08-12 2009-04-09 Actavis Group Hf Verwendung von cgrp-antagonisten-verbindungen zur behandlung von psoriasis
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
WO2009033809A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US20190240293A1 (en) 2016-07-26 2019-08-08 Flagship Pioneering Innovations V, Inc. Neuromodulating compositions and related therapeutic methods for the treatment of cancer by modulating an anti-cancer immune response

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6019967A (en) * 1995-01-26 2000-02-01 Societe L'oreal S.A. Therapeutic/cosmetic compositions comprising CGRP antagonists for treating sensitive human skin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
(MedlinePlus Medical Encyclopedia, [online]. Update date: 11/22/2011. U.S. National Library of Medicine, NIH. [retrieved on 09/21/2012]. Retrieved from the Internet: . Psoriasis. see pages 1-5). *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10668132B2 (en) 2002-08-12 2020-06-02 Nepsone Ehf Use of CGRP antagonist compounds for treatment of psoriasis
US11266718B2 (en) * 2002-08-12 2022-03-08 Nepsone Ehf Methods of treating inflammatory skin disorders
US11433119B2 (en) * 2016-11-18 2022-09-06 Nepsone Ehf Methods of treating inflammatory skin disorders
US11517612B2 (en) 2016-11-18 2022-12-06 Nepsone Ehf Methods of treating inflammatory skin disorders

Also Published As

Publication number Publication date
BR0313388A (pt) 2005-07-05
ES2323170T3 (es) 2009-07-08
CN1674919A (zh) 2005-09-28
EA008744B1 (ru) 2007-08-31
CA2495498A1 (en) 2004-02-19
ATE423553T1 (de) 2009-03-15
DK1556020T3 (da) 2009-06-22
KR101070213B1 (ko) 2011-10-06
KR20050056198A (ko) 2005-06-14
CA2495498C (en) 2014-04-15
MXPA05001649A (es) 2005-05-27
EA200500306A1 (ru) 2005-08-25
IL166761A (en) 2010-12-30
US20170065681A1 (en) 2017-03-09
SI1556020T1 (sl) 2009-08-31
IL166761A0 (en) 2006-01-15
IS2902B (is) 2014-10-15
RS20050132A (en) 2007-11-15
RS52750B (sr) 2013-08-30
EP1556020A2 (en) 2005-07-27
US20230181693A1 (en) 2023-06-15
US20140220030A1 (en) 2014-08-07
EP1556020B1 (en) 2009-02-25
PT1556020E (pt) 2009-05-29
AU2003260944B2 (en) 2009-05-14
US11266718B2 (en) 2022-03-08
PL375536A1 (en) 2005-11-28
IS7741A (is) 2005-03-14
US10668132B2 (en) 2020-06-02
US20200338168A1 (en) 2020-10-29
NZ538615A (en) 2008-03-28
AU2003260944A1 (en) 2004-02-25
JP2006501216A (ja) 2006-01-12
NO20051262L (no) 2005-03-11
DE60326370D1 (de) 2009-04-09
WO2004014351A2 (en) 2004-02-19
WO2004014351A3 (en) 2004-06-17
US9585940B2 (en) 2017-03-07

Similar Documents

Publication Publication Date Title
US9585940B2 (en) Use of CGRP antagonist compounds for treatment of psoriasis
Giraudo et al. Rat hypothalamic NPY mRNA and brown fat uncoupling protein mRNA after high-carbohydrate or high-fat diets
Paolieri et al. Terfenadine and fexofenadine reduce in vitro ICAM-1 expression on human continuous cell lines
KR20090063209A (ko) 신경병증성 통증에서 진통의 유도
Vaillend et al. Spatial discrimination learning and CA1 hippocampal synaptic plasticity in mdx and mdx3cv mice lacking dystrophin gene products
Okamoto et al. Ventromedial hypothalamus suppresses splenic lymphocyte activity through sympathetic innervation
Hanf et al. Substance P induced histamine release from nasal mucosa of subjects with and without allergic rhinitis
DE60207043T2 (de) Histidin-reiches glykoprotein (hrgp) zur inhibierung der angiogenese
JP2005506966A (ja) ノイロキニン１受容体拮抗剤による毛包の処置
Ma et al. Impaired renal sensory responses after renal ischemia in the rat
Erin et al. Differentiation of neuronal from non-neuronal Substance P
Tröltzsch et al. The calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS reduces neurogenic increases in dural blood flow
US11433119B2 (en) Methods of treating inflammatory skin disorders
Tsilioni et al. Effects of an extract of salmon milt on symptoms and serum TNF and substance P in patients with fibromyalgia syndrome
Xu et al. Intermedin improves cardiac function and sympathetic neural remodeling in a rat model of post myocardial infarction heart failure
Lee et al. Effect of endothelin receptor antagonists on ventricular susceptibility in postinfarcted rats
Bolitho et al. Vascularity during wound maturation correlates with fragmentation of serum albumin but not ceruloplasmin, transferrin, or haptoglobin
Cao et al. Lack of a significant effect of deletion of the tachykinin neurokinin-1 receptor on wound healing in mouse skin
Hwang et al. Effects of granulocyte macrophage Colony-stimulating factor inhibition on the skin/nerve cell model in vitro
JP5697099B2 (ja) 掻痒抑制剤
I'anson et al. Histaminergic regulation of seasonal metabolic rhythms in Siberian hamsters
Sudlow Actions of lipocortin-1 on the immune-hypothalamic-pituitary-adrenal axis
Misumi et al. Consistently nonoverlapping distribution of epidermal growth factor receptors in adult human skin detected by various monoclonal antibodies
Eiland Functional and comparative aspects of sleep and wakefulness

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION